Implications of the FDA draft guidance on biosimilars for clinicians: what we know and don't know

MeSH terms

• Biosimilar Pharmaceuticals / pharmacokinetics
• Biosimilar Pharmaceuticals / therapeutic use*
• Drug Approval / methods
• Drug Substitution
• Health Knowledge, Attitudes, Practice*
• Health Plan Implementation / legislation & jurisprudence
• Health Plan Implementation / methods
• Humans
• Off-Label Use / legislation & jurisprudence
• Physicians / legislation & jurisprudence
• Practice Guidelines as Topic*
• Research Report
• Therapeutic Equivalency
• United States
• United States Food and Drug Administration / legislation & jurisprudence*